hackint0sh/New-Dataset huggingface dataset:
Researchers will compare the autistic and the non-autistic groups to see if statistical learning plays a similar or different role in predicting children's language and literacy growth. conditions: Autism Spectrum Disorder conditions: Language Development conditions: Literacy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Structural vs. Random sequences of stimuli name: Intact vs. Degraded speech name: Repeating 5-syllable nonwords or 2-syllable nonwords name: Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data. measure: Language Composite Score measure: Reading Composite Score measure: Language/Literacy Disorder Status measure: Neural similarity between language and statistical learning tasks measure: Orthographic statistical sensitivity measure: Phonological statistical sensitivity measure: Linguistic SL composite scores measure: Neural sensitivity to statistical regularities during the statistical learning tasks measure: Neural activation to statistical regularities during the language tasks sex: ALL minimumAge: 72 Months maximumAge: 90 Months stdAges: CHILD facility: Northeastern University status: RECRUITING city: Boston state: Massachusetts zip: 02115 country: United States name: Brynn Siles, BS role: CONTACT phone: 617-830-1530 email: plausl.project@gmail.com name: Zhenghan Qi, MD/PhD role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Boston University status: ENROLLING_BY_INVITATION city: Boston state: Massachusetts zip: 02215 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06332131 id: UPCC07623 briefTitle: Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2027-04 date: 2024-03-27 date: 2024-04-10 name: Abramson Cancer Center at Penn Medicine class: OTHER briefSummary: This is an observational study that includes patients with melanoma who will be treated with adjuvant immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system. conditions: Melanoma conditions: Coronary Microvascular Dysfunction conditions: Cardiotoxicity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 25 type: ESTIMATED measure: Incidence of new abnormal myocardial blood flow reserve (MBFR) measure: Incidence of major cardiovascular events measure: Coronary calcium score measure: All cause mortality measure: Cardiovascular specific mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Abramson Cancer Center at University of Pennsylvania city: Philadelphia state: Pennsylvania zip: 19104 country: United States lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06332118 id: avf ice massage briefTitle: The Effect of Ice Massage on Pain, Ecchymosis, Hematoma and Patient Satisfaction overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-05-15 date: 2024-05-30 date: 2024-03-27 date: 2024-04-02 name: Erzurum Technical University class: OTHER briefSummary: The research was planned to measure pain, ecchymosis, hematoma and patient satisfaction with ice massage applied to the fistula before the arteriovenous fistula procedure in hemodialysis patients. Patients who agree to participate in the study will be given ice massage before the procedure and the relevant parameters will be measured. conditions: Hemodialysis Complication studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The research is quasi-experimental and relationship-seeking in a pretest-posttest format. primaryPurpose: PREVENTION masking: NONE count: 35 type: ESTIMATED name: ice massage group measure: Pain score measure: Ecchymosis degree measure: Hematoma degree measure: Patient satisfaction score sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ercan Bakır city: Erzurum state: Yakutiye zip: 25010 country: Turkey name: Ercan Bakır, PhD role: CONTACT phone: 05444252111 email: ercan.bakir@erzurum.edu.tr name: Ercan Bakır, PhD role: CONTACT phone: 05443047186 email: e.bakir02@gmail.com lat: 39.90861 lon: 41.27694 facility: Ercan Bakır city: Erzurum state: Yakutiye country: Turkey lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06332105 id: CUK001 briefTitle: Evaluation of Low Phenylalanine Formulas overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-30 date: 2025-01 date: 2025-04 date: 2024-03-27 date: 2024-04-15 name: Ajinomoto Co., Inc. class: INDUSTRY name: Birmingham Children's Hospital name: Great Ormond Street Hospital for Children NHS Foundation Trust briefSummary: Ajinomoto Cambrooke has developed a PKU protein substitute that is a proprietary blend of purified Glycomacropeptide (GMP) and essential amino acids, under the brand name Glytactin®. One serving of such Glytactin® products contains 20mg or less of Phenylalanine (Phe). The aim of the proposed study is to use this purified GMP-AA-based protein substitute, with less Phe per gram of protein equivalent than other commercially available products, in children with PKU at 100% of their protein substitute intake and evaluate its efficacy and the change in blood Phe in comparison to Phe-free L-AA-based protein substitutes. conditions: Phenylketonurias studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: 2-stage, 15-week randomized crossover trial. primaryPurpose: TREATMENT masking: NONE count: 19 type: ESTIMATED name: Glytactin name: L-AA measure: Change in blood Phe in sex: ALL minimumAge: 3 Years maximumAge: 16 Years stdAges: CHILD facility: Birmingham Women and Children's Hospital city: Birmingham state: West Midlands zip: B4 6NH country: United Kingdom lat: 52.48142 lon: -1.89983 facility: Great Ormond Street Hospital for Children city: London zip: WC1N 3JH country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06332092 id: FID-007-003 briefTitle: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma acronym: HNSCC overallStatus: RECRUITING date: 2024-04-10 date: 2025-03-31 date: 2025-12-31 date: 2024-03-27 date: 2024-04-17 name: Fulgent Pharma LLC. class: INDUSTRY briefSummary: The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to characterize the safety and tolerability. Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab in each 28-day cycle. conditions: Head and Neck Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Two different dosing regimens of FID-007 in combination with fixed-dose Cetuximab primaryPurpose: TREATMENT masking: NONE count: 46 type: ESTIMATED name: FID007 measure: ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) measure: BOR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) measure: Duration of Response (DoR) measurement measure: Progression-free Survival (PFS) measurement measure: Overall Survival (OS) measurement measure: Disease Control Rate (DCR) analysis measure: Adverse Events (AEs) graded according to the CTCAE version 5.0 measure: Vital Signs safety assessments measure: Clinical Laboratory safety assessments measure: ECGs safety assessment measure: Area Under the Plasma Concentration Versus Time Curve (AUC) of FID-007 measure: Peak Plasma Concentration (Cmax) measure: Terminal/elimination half-life (t1/2) measure: Clearance (CL) measure: Volume of Distribution (Vd) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gabrail Cancer Center Research status: RECRUITING city: Canton state: Ohio zip: 44718 country: United States name: Nashat Gabrail, MD role: CONTACT lat: 40.79895 lon: -81.37845 hasResults: False
nctId: NCT06332079 id: HAITI 2023-505356-22-00 briefTitle: Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients acronym: HAITI overallStatus: RECRUITING date: 2024-03-13 date: 2026-11 date: 2027-02 date: 2024-03-27 date: 2024-03-27 name: Gruppo Oncologico del Nord-Ovest class: OTHER briefSummary: The aim of this study is to assess the efficacy of 166Ho-TARE followed by maintenance therapy with fluoropyrimidine and anti-EGFR or bevacizumab in liver-limited unresectable colorectal cancer patients, in terms of progression free rate 9- and 8-months for cohort A and B, respectively. conditions: Colorectal Cancer Metastatic studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Two cohorts of patients will be included according to the two main prognostic populations in mCRC (left sided, RAS/BRAF wild-type and, right-sided and/or RAS mutated tumors) treated with different maintenance therapy (fluoropyrimidine plus anti-EGFR or bevacizumab).
A total of 23 patients will be enrolled in each cohort. primaryPurpose: TREATMENT masking: NONE count: 46 type: ESTIMATED name: 166Holmium TARE name: Cetuximab name: Panitumumab name: 5-Fluorouracil name: Bevacizumab name: Capecitabine measure: Progression-free survival (PFS) Rate measure: Overall Toxicity rate measure: Grade 3/ Grade 4 Toxicity rate measure: Post-treatment Disease Control Rate (DCR) measure: Progression free survival measure: Overall Survival measure: Dose-response relationships measure: Quality of Life (QoL) assessed using the EORTC QLQ-CR29 questionnaire measure: Quality of Life (QoL) assessed using the EORTC QLQ-CR30 questionnaire measure: Quality of Life (QoL) assessed using the EuroQol EQ-5D questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliero Universitaria Pisana status: RECRUITING city: Pisa zip: 56126 country: Italy name: Beatrice Borelli, MD, PhD role: CONTACT phone: +39050992192 email: b.borelli89@gmail.com name: Gianluca Masi, MD role: PRINCIPAL_INVESTIGATOR name: Beatrice Borelli, MD, PhD role: SUB_INVESTIGATOR lat: 43.70853 lon: 10.4036 hasResults: False
nctId: NCT06332066 id: 0046-24-COM briefTitle: Oxytocin Administration to Therapists and Its Effects on Patient-perceived Attunement and Responsiveness overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-05-30 date: 2024-06-30 date: 2024-03-27 date: 2024-03-27 name: Shalvata Mental Health Center class: OTHER name: Clalit Health Services briefSummary: In recent years there is a great interest in the possible role of Oxytocin (OT) as a facilitator for enhancing psychotherapeutic processes in patients with mental illnesses. Specific studies explored OT administration to patients, and the effect on psychotherapy on interaction within the therapeutic dyad. Nonetheless, studies exploring OT's effects of the therapists' side of the therapeutic dyad on the psychotherapy session and outcome, have not been conducted. The current study aims to assess the effect of OT administration to the therapists of psychiatric outpatients, on treatment process and outcome and specifically on the patient and therapist experience of the attunement and responsiveness toward the patient in the therapeutic encounter. Twenty staff members from Teradion Mental health Clinic of Clalit Health Services will be recruited, as well as 100 patients treated by these staff members. Therapists agreeing to participate will receive OT and PLC in a random order, at the same day they are seeing the same patients and the consecutive week. Patients agreeing to participate will complete a demographic questionnaire and all study measures, and will be scheduled to perform two consecutive research sessions with their therapists. The therapist will receive either OT or PLC in each of these two sessions, and right after the session the patients will complete the assessment scales. Multilevel models will be performed by the investigators to assess the effects of OT administration in therapists receiving OT versus receiving placebo. This research will be performed in accordance with ethical principles of Helsinki WMA Declaration. This study is the first to assess the effectiveness of hormonal augmentation for therapists and its influence on therapeutic process with patients suffering from acute distress in the public mental health domain. conditions: Mental Health Therapists studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Oxytocin nasal spray measure: Attunement and Responsiveness towards patients measure: Attachment with Therapist measure: Working Alliance with Therapist measure: Patient Symptoms sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mental Health Clinic, Teradion city: Misgav country: Israel name: Ayelet Nir,, M.A. role: CONTACT phone: 972-4-6025050 email: ayeletni1@clalit.org.il name: Galit role: CONTACT phone: 972-4-6026050 lat: 32.86017 lon: 35.26165 hasResults: False
nctId: NCT06332053 id: SY-5007-I-03 briefTitle: A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-06-01 date: 2024-06-01 date: 2024-03-27 date: 2024-03-27 name: Shouyao Holdings (Beijing) Co. LTD class: OTHER briefSummary: This study is a single-center, open-lable and fixed sequence test conducted in healthy subjects to evaluate the pharmacokinetic effects of Itraconazole and Rifampicin on a single dose of SY-5007 Oral administration. It is planned to enroll 28 healthy subjects and assign them to two parallel test groups, Group A (SY-5007 combined with Itraconazole) and Group B (SY-5007 combined with Rifampicin). conditions: Healthy Subjects studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: SY-5007 name: Itraconazole name: SY-5007 name: Rifampin measure: Cmax for SY-5007 measure: Tmax for SY-5007 measure: AUC0-t for SY-5007 measure: AUC0-∞ for SY-5007 measure: t½ for SY-5007 measure: CL/F for SY-5007 measure: Vz/F for SY-5007 measure: Safety of SY-5007 sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: West China Hospital of Sichuan University city: Chengdu state: Sichuan zip: 610041 country: China name: Li Zheng role: CONTACT phone: 86-28-85423655 email: zhengli@wchscu.cn lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06332040 id: 22-500-243-50-35 briefTitle: Gentamicin Bladder Instillation on CAUTI overallStatus: RECRUITING date: 2023-10-09 date: 2026-10-08 date: 2026-10-08 date: 2024-03-26 date: 2024-03-26 name: St. Joseph's Hospital and Medical Center, Phoenix class: OTHER briefSummary: Urinary tract infections in catheterized patients is an unacceptable complication and has been termed a 'never event' by the Center for Medicare \& Medicaid Services (CMS); however there is not consensus among clinicians on how to best prevent CAUTIs. We propose a prospective randomized controlled trial to test the efficacy of prophylactic gentamicin bladder irrigation in elimination of CAUTIs. conditions: Catheter Infection studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 400 type: ESTIMATED name: Gentamicin measure: CAUTI as primary outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St. Jpseph's Hospital and Medical Center status: RECRUITING city: Phoenix state: Arizona zip: 85013 country: United States name: Kristina Kupanoff, PhD role: CONTACT phone: 602-406-5192 email: Kristina.Kupanoff@Commonspirit.org lat: 33.44838 lon: -112.07404 hasResults: False
nctId: NCT06332027 id: Soh-Med-24-03-03MD briefTitle: Accuracy of Hystro-Salpingo-Foam-Sonography (HYFOSY) as Tubal Patency Test in Comparison to Laparoscopy in Infertile Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-04-01 date: 2024-03-26 date: 2024-03-26 name: Sohag University class: OTHER briefSummary: Tubal patency testing is an essential part of female subfertility evaluation . Tubal abnormalities are seen in 30-40% of female subfertility patients . Laparoscopy with chromopertubation is considered to be the gold standard diagnostic procedure .
Hysterosalpingo-Contrast Sonography (HyCoSy) was introduced as an alternative using either contrast media or saline. The accuracy of HyCoSy is comparable to that of HSG and LSC being reference standards for tubal patency testing.However, hyperechogenic contrast media such as Echovist_ (Schering AG, Berlin) and SonoVue_ (Bracco, Milan)are either no longer available or not licensed for tubal patency testing.
Hysterosalpingo-Foam Sonography (HyFoSy) was developed as an alternative for contrast HyCoSy and was introduced in 2010 as a first-line office tubal patency test.Foam is used in the HyFoSy technique to visualize the fallopian tubes and is created by rigorously mixing 5mlExEm_-gel (containing hydroxyethyl cellulose and glycerol,IQMedical Ventures BV, Rotterdam, TheNetherlands) with 5ml purified ExEm_-water.
In 2017, HyLiFoSy combined with power Doppler (PD)(HyLiFoSy-PD) technique was described as a possibly less painful and easier to detect on ultrasound alternativeto HyFoSy and HyCoSy, which can be used whenever the contrast media used with both are either unavailable or is relatively expensive Ultrasound-based tubal patency tests include hysterosalpingo-contrast sonography (HyCoSy), hysterosalpingo-foam sonography (HyFoSy), and hysterosalpingo-lidocaine-foam sonography (HyLiFoSy)and have shown a high detection rate of tubal obstruction and good reproducibility with concordances from 83.8 to 100% with HSG, and from 78.1 to96.91% with lap-and-dye test.
In addition, they allow for a single comprehensive assessment of the uterus and the fallopian tubes and it can be performed by the same specialist who indicates it, in the clinician's own office with it consequently being time efficient. Finally, some studies have shown an increase in the rate of post-procedure gestation. conditions: Infertility, Female studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 122 type: ESTIMATED name: Hystro-Salpingo-Foam-Sonography (HYFOSY) measure: the accuracy of HyFoSy in the assessment of tubal patency sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Sohag University Hospital city: Sohag country: Egypt name: Magdy M Amin, Professor role: CONTACT lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06332014 id: 20210123 briefTitle: Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2026-07-29 date: 2026-07-29 date: 2024-03-26 date: 2024-03-26 name: Amgen class: INDUSTRY briefSummary: The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months. conditions: Osteoporosis studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Prolia measure: Percent change from baseline in bone mineral density (BMD) of lumbar spine at month 12 measure: Percent change from baseline in serum C-terminal telopeptide (CTx) at month 3, 6, 9, and 12 measure: Percent change from baseline in serum procollagen Type 1 N-Telopeptide (P1NP) at month 3, 6, 9, and 12 measure: Percent change from baseline in total hip and femoral neck BMD at month 6 and 12 measure: Percent change from baseline in lumbar spine BMD at month 6 measure: Number of participants with adverse events (AE) sex: MALE minimumAge: 30 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06332001 id: IEO 1403 briefTitle: Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance overallStatus: RECRUITING date: 2020-12-31 date: 2024-12-31 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: European Institute of Oncology class: OTHER briefSummary: This is a randomized controlled trial for the evaluation of the acceptability of Whole-Body-Magnetic Resonance Imaging (WB-MRI) based on music and comunication intervention compared to a standard care condition.
Subjects will be randomized into two groups: the experimental group or arm that receives the music and interaction interventions, and the control group or arm that receives a standard care condition. conditions: Neoplasm Malignant studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Experimental Group name: Control Group measure: Acceptability of WB-MRI based on music and comunication intervention compared to a standard care condition. measure: Measure the level of patient's distress pre and post WB-MRI in the two groups using Distress Thermometer (V2.2020) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: IEO Istituto Europeo di Oncologia status: RECRUITING city: Milan zip: 20141 country: Italy name: Giuseppe Petralia role: CONTACT email: giuseppe.petralia@ieo.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06331988 id: IEO 1341 briefTitle: Microbiome, Immune-system and Tumor Interaction in Colorectal Cancer acronym: MITICO overallStatus: RECRUITING date: 2022-07-21 date: 2026-07-31 date: 2029-07-31 date: 2024-03-26 date: 2024-03-27 name: European Institute of Oncology class: OTHER briefSummary: Colorectal cancers represent the second leading cause of cancer-related death in the United States Western world. In Italy they represent the second most frequent neoplasm (49,000 cases in 2019). Despite the advancement of surgical techniques and medical therapy programs systemic, it is estimated that approximately 40-50% of colorectal cancers recur after being treated for a limited loco-regional disease. Patients who develop metastases throughout their history clinic have a 5-year overall survival of just over 10%.
It has now become urgent to overcome the T-tumor N-node M- metastasis (TNM) staging, to have more modern knowledge on the factors capable of impacting significantly on the prognosis, influence the real risk of disease recurrence, Identify new prognostic categories and subcategories, therefore being able to predict the clinical benefit of treatments that can be more targeted, personalized and effective. In this panorama it has developed in recent years an ever-growing literature also regarding the role of bacterial flora intestinal (microbiota) in patients with colorectal cancer. In particular, recent discoveries have highlighted the immunoregulatory role of the microbiota in the anti-tumor response. This study aims of evaluating how the molecular characteristics of the tumor, of the infiltrating immune system cells and of the associated intestinal microbiota correlate with the development of colorectal cancer, its progression and response to treatments. conditions: Colorectal Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 320 type: ESTIMATED measure: Relapse free survival measure: Overall survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan zip: 20141 country: Italy name: Davide Ciardiello, MD role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 hasResults: False